- Home
- OPP vs BDTX Comparison
OPP vs BDTX Comparison
Compare OPP & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
HOLD
Current Price
$2.57
Company Overview
Basic Information| Metric | OPP | BDTX |
|---|---|---|
| Founded | 2010 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 204.0M | 220.3M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | OPP | BDTX |
|---|---|---|
| Price | $7.83 | $2.57 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $10.60 |
| AVG Volume (30 Days) | 108.0K | ★ 1.6M |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | ★ 14.41% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.38 |
| Revenue | N/A | ★ $70,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $6.85 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.26 | $1.20 |
| 52 Week High | $8.83 | $4.94 |
Technical Indicators
Market Signals| Indicator | OPP | BDTX |
|---|---|---|
| Relative Strength Index (RSI) | 37.04 | 28.57 |
| Support Level | $7.94 | $2.61 |
| Resistance Level | $8.03 | $2.72 |
| Average True Range (ATR) | 0.07 | 0.25 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 25.00 | 20.18 |
Price Performance
Historical Comparison OPP
BDTX
About OPP RiverNorth/DoubleLine Strategic Opportunity Fund Inc.
RiverNorth/DoubleLine Strategic Opportunity Fund Inc is a closed-end management investment company. The company's investment objective is to seek current income and overall total return.
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.